US-based Bruker Corporation has announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants.
New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterization, and eXd-enabled glycoproteomics for deeper biological, disease and drug discovery insights.
Similarly, the now enabled timsOmni deep proteoform methods are equally powerful in interrogating drug targets, as well as biologics, including therapeutic antibodies, ADCs, multispecifics, and their PTM distributions and glyco-heterogeneity.
The latest version OmniScape™ 2026b strengthens timsOmni proteoform workflows by integrating the novel OmniWave™ algorithm, which enables top-down sequencing and proteoform identification at scale with high-confidence annotation of critical PTMs that drive disease signaling. Researchers can now move beyond protein group read-outs to proteoform-centric mechanisms, e.g., distinguishing signaling relevant protein variants that indicate disease states or treatment response.
Bruker is introducing a new de novo peptide sequencing workflow in Bruker ProteoScape v2026b software that pairs an AI‑enhanced scoring model—trained on more than seven million MS/MS spectra—with a proven dynamic‑programming foundation to deliver accurate de novo sequences from high‑resolution timsTOF data.
Bruker is greatly enhancing glycoproteomics with support for trapped electron‑based dissociation (eXd) data in GlycoScape software, enabling confident glycopeptide characterization while preserving fragile glycan structures and supporting localization and topology insights.
